TW200745164A - Gene recombination antibodies composition - Google Patents

Gene recombination antibodies composition

Info

Publication number
TW200745164A
TW200745164A TW095126880A TW95126880A TW200745164A TW 200745164 A TW200745164 A TW 200745164A TW 095126880 A TW095126880 A TW 095126880A TW 95126880 A TW95126880 A TW 95126880A TW 200745164 A TW200745164 A TW 200745164A
Authority
TW
Taiwan
Prior art keywords
gene recombination
antibody
antibodies
compositon
transform
Prior art date
Application number
TW095126880A
Other languages
English (en)
Other versions
TWI397536B (zh
Inventor
Kenya Shitara
Rinpei Niwa
Akito Natsume
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of TW200745164A publication Critical patent/TW200745164A/zh
Application granted granted Critical
Publication of TWI397536B publication Critical patent/TWI397536B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW095126880A 2005-07-22 2006-07-21 基因重組之抗體組成物 TWI397536B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005212979 2005-07-22
JP2006108216 2006-04-11

Publications (2)

Publication Number Publication Date
TW200745164A true TW200745164A (en) 2007-12-16
TWI397536B TWI397536B (zh) 2013-06-01

Family

ID=37668912

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095126880A TWI397536B (zh) 2005-07-22 2006-07-21 基因重組之抗體組成物

Country Status (9)

Country Link
EP (1) EP1921090B1 (zh)
JP (1) JP4997108B2 (zh)
KR (1) KR101318611B1 (zh)
CN (1) CN101287765B (zh)
AU (1) AU2006270718B2 (zh)
CA (1) CA2616256C (zh)
ES (1) ES2534000T3 (zh)
TW (1) TWI397536B (zh)
WO (1) WO2007011041A1 (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008090960A1 (ja) * 2007-01-24 2010-05-20 協和発酵キリン株式会社 ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
WO2008090958A1 (ja) * 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
WO2008090959A1 (ja) * 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. エフェクター活性が増強された遺伝子組換え抗体組成物
BRPI0810472A2 (pt) * 2007-04-16 2014-11-11 Momenta Pharmaceuticals Inc Métodos relacionados à glicosilação da superfície celular
WO2009142186A1 (ja) 2008-05-20 2009-11-26 株式会社カネカ 細胞障害性組成物
US9023999B2 (en) 2008-06-30 2015-05-05 Kyowa Hakko Kirin Co., Ltd Anti-CD27 antibody
ES2602459T3 (es) * 2008-12-26 2017-02-21 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-CD4
CN102782131B (zh) 2010-03-02 2015-08-05 协和发酵麒麟株式会社 修饰抗体组合物
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
JP2013177317A (ja) * 2010-06-24 2013-09-09 Meneki Seibutsu Kenkyusho:Kk 抗ｐｄｇｆ受容体抗体
HUE039412T2 (hu) 2010-11-23 2018-12-28 Glaxo Group Ltd Antigén megkötõ proteinek oncostatin M (OSM) megkötésére
EP2853542A1 (en) 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
DK3415531T3 (da) 2011-05-27 2023-09-18 Glaxo Group Ltd Bcma (cd269/tnfrsf17)-bindende proteiner
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
JP5987057B2 (ja) 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
WO2013181568A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to alemtuzumab
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
ES2691794T3 (es) 2012-12-07 2018-11-28 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-FOLR1
KR20150135231A (ko) 2013-01-28 2015-12-02 에베크 인코포레이티드 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
JP6224739B2 (ja) 2013-03-15 2017-11-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗ｌａｇ−３結合タンパク質
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CA2995639A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-lag-3 antibodies
CN106191072A (zh) * 2016-08-04 2016-12-07 沈沭彤 重组人源嵌合GcFc基因片段及融合蛋白
US20220233597A1 (en) 2019-06-13 2022-07-28 Societe Des Produits Nestle S.A. Use of whey protein micelles for controlling postprandial glucose response
CA3143211A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
IL310698A (en) 2021-08-13 2024-04-01 Glaxosmithkline Ip Dev Ltd Cytotoxic targeting chimeras for CCR2-expressing cells
CA3227835A1 (en) 2021-08-13 2023-02-16 Peiling CHEN Cytotoxicity targeting chimeras
WO2023161881A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023161879A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161875A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
WO2023161876A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161874A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
WO2023161877A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for integrin avb6-expressing cells
WO2023161878A1 (en) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for folate receptor-expressing cells
WO2023212304A1 (en) 2022-04-29 2023-11-02 23Andme, Inc. Antigen binding proteins
WO2024042112A1 (en) 2022-08-25 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2706116A1 (en) * 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins

Also Published As

Publication number Publication date
EP1921090B1 (en) 2015-01-14
CA2616256C (en) 2016-10-25
CN101287765B (zh) 2013-03-27
CN101287765A (zh) 2008-10-15
CA2616256A1 (en) 2007-01-25
ES2534000T3 (es) 2015-04-16
KR20080039907A (ko) 2008-05-07
EP1921090A4 (en) 2009-08-19
WO2007011041A1 (ja) 2007-01-25
JPWO2007011041A1 (ja) 2009-02-05
KR101318611B1 (ko) 2013-11-13
EP1921090A1 (en) 2008-05-14
AU2006270718B2 (en) 2011-07-21
TWI397536B (zh) 2013-06-01
AU2006270718A1 (en) 2007-01-25
JP4997108B2 (ja) 2012-08-08

Similar Documents

Publication Publication Date Title
TW200745164A (en) Gene recombination antibodies composition
RU2012129735A (ru) Антитела к her3 и их применения
RU2363706C2 (ru) Антитела к рецептору инсулиноподобного фактора роста i и их применение
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
WO2008090959A1 (ja) エフェクター活性が増強された遺伝子組換え抗体組成物
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
PE20130159A1 (es) Anticuerpos anti-cd40
HRP20160131T1 (hr) Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba
RU2012142230A (ru) Антитела против csf-1r человека и их применение
WO2008090960A1 (ja) ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
RU2012142231A (ru) Антитела против csf-1r человека и их применение
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
RU2010111751A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
RU2009147758A (ru) Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
NZ591471A (en) Antibodies to ccr2
RU2015144105A (ru) Антитела к гепсидину и их применения
NZ598063A (en) Gram-positive bacteria specific binding compounds
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
MX2009006891A (es) Anticuerpos cd44.